James G. Christensen

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

Eunice L. Kwak, Yung‐Jue Bang, D. Ross Camidge et al. · New England Journal of Medicine · 2010 · 4.5K citations

Medicine, Oncology, Pharmacology +14

<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi et al. · Science · 2007 · 4.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

Lecia V. Sequist, Belinda A. Waltman, Dora Dias‐Santagata et al. · Science Translational Medicine · 2011 · 3.6K citations · Full text

Medicine, Genetics, Oncology +17

Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer

Alice T. Shaw, Sai‐Hong Ignatius Ou, Yung‐Jue Bang et al. · New England Journal of Medicine · 2014 · 2K citations

Medicine, Oncology, Pharmacology +17

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

Dirk B. Mendel, Alexander Laird, Xiaohua Xin et al. · PubMed · 2003 · 2K citations

Medicine, Oncology, Pharmacology +15